History

History

Shortly after its founding in February 2005, Chiome Bioscience Inc. concluded a collaboration agreement with RIKEN (The Institute of Physical and Chemical Research) to commercialize its leading technology, the ADLib® system. After the launching research activities, Chiome Bioscience Inc. concluded a collaboration agreement with Chugai Pharmaceutical Co., Ltd., which led to new business projects, including research support services for antibody drugs based on the ADLib® system.

The following corporate history shows the key development dates in the history of Chiome Bioscience Inc.

Year Month Corporate History
2005 February Chiome Bioscience Inc. (capital: 10 million yen) was established in the Bunkyo district of Tokyo to commercialize the ADLib® system developed through the collaboration of the Genetic Dynamics Research Unit at RIKEN, headed by Dr. Kunihiro Ohta (currently serving as an Executive Director at Chiome Bioscience Inc.), and the Saitama Small and Medium Enterprise Development Corporation (currently Saitama Industrial Development Corporation).
April Chiome Bioscience Inc. concluded an agreement with RIKEN to commercialize the ADLib® system, and research activities begins.
May ADLib® System was described in the journal Nature Biotechnology as “an innovative rapid antibody generating technology to be the first in the world that employs promotion of DNA recombination.”
July CHIOME has obtained an exclusive license to commercialize platform technology (the ADLib® System) from RIKEN Institute and the Japanese Science and Technology Agency. And CHIOME can sublicense this technology to other third parties.
2007 July Chiome Bioscience Inc. concluded collaboration agreement with Chugai Pharmaceutical Co., Ltd. For antibody production using the ADLib® system.
2008 May The R&D Division has relocated to RIKEN-WAKO Incubation Plaza to allow for the expansion of research facilities.
October Chiome Bioscience Inc. concluded a collaboration agreement with Yokohama City University for antibody production using the ADLib® System.
November Chiome Bioscience Inc. concluded an alliance agreement with Chugai Pharmaceutical Co., Ltd. for the generation of development-candidate antibodies using the ADLib® system.
2009 October The head office has relocated to Shinjuku ward, Tokyo.
2010 April Chiome Bioscience Inc. concluded a collaboration agreement with Japanese Foundation for Cancer Research (JFCR) for antibody production using the ADLib® system.
August Chiome Bioscience Inc. concluded a payment based technology transfer agreement with the Japan Science and Technology Agency on the platform technology - the ADLib® System.
September Chiome Bioscience Inc. concluded an agreement with Fujirebio Inc. for licensing of the ADLib® system and collaborative R&D.
2011 January Chiome Bioscience Inc. concluded an agreement on exploitation of joint invention with RIKEN.
November Chiome Bioscience Inc. concluded a collaboration agreement with Five Prime Therapeutics, Inc. for antibody production using the ADLib® System.
December CHIOME is now listed on Tokyo Stock Exchange Mothers Index.
2012 February Chiome Bioscience Inc. concluded a comprehensive joint research agreement with the Shizuoka Cancer Center for antibody production using the ADLib® System.
April Chiome Bioscience Inc. concluded a collaboration agreement with the Glaxo Group Limited for antibody production using the ADLib® System.
July Chiome Bioscience Inc. concluded a collaboration agreement with the National Cancer Center of Japan for antibody production using the ADLib® System.
August Chiome Bioscience Inc. concluded a Master Service Agreement with Chugai Pharmabody Research Pte. Ltd. on preparation of research materials necessary for effective development of antibody drug.
2013 January Chiome Bioscience Inc. concluded a Co-Development and Exclusive Option Agreement with Biotecnol, Inc. for antibody production using the ADLib® System.
May The head office has relocated to Shibuya ward, Tokyo.
June Chiome Bioscience Inc. concluded a License Agreement with Fujirebio Inc. for manufacture and sale of diagnostic kits that employs a specific antibody obtained using the ADLib® System.
December Chiome Bioscience Inc. acquired a majority of Liv Tech, Inc.'s capital.
2014 January In Europe, Fujirebio Inc. started to sell diagnostic kits that employs a specific antibody obtained using the ADLib® System.
March Chiome Bioscience Inc. constructed the Fully Human ADLib® System.
2015 July Chiome Bioscience Inc. merged with Liv Tech, Inc.